Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

A π-Halogen Bond of Dibenzofuranones with the Gatekeeper Phe113 in Human Protein Kinase CK2 Leads to Potent Tight Binding Inhibitors.

Schnitzler A, Gratz A, Bollacke A, Weyrich M, Kuckländer U, Wünsch B, Götz C, Niefind K, Jose J.

Pharmaceuticals (Basel). 2018 Feb 17;11(1). pii: E23. doi: 10.3390/ph11010023.

2.

Self-Assembled Supramolecular Nanoparticles Improve the Cytotoxic Efficacy of CK2 Inhibitor THN7.

Nacereddine A, Bollacke A, Róka E, Marminon C, Bouaziz Z, Fenyvesi F, Bácskay IK, Jose J, Perret F, Le Borgne M.

Pharmaceuticals (Basel). 2018 Jan 26;11(1). pii: E10. doi: 10.3390/ph11010010.

3.

Identification of a Potent Allosteric Inhibitor of Human Protein Kinase CK2 by Bacterial Surface Display Library Screening.

Nienberg C, Garmann C, Gratz A, Bollacke A, Götz C, Jose J.

Pharmaceuticals (Basel). 2017 Jan 5;10(1). pii: E6. doi: 10.3390/ph10010006.

4.

Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.

Bollacke A, Nienberg C, Borgne ML, Jose J.

J Pharm Biomed Anal. 2016 Mar 20;121:253-260. doi: 10.1016/j.jpba.2016.01.011. Epub 2016 Jan 8.

PMID:
26786382
5.

Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.

Gozzi GJ, Bouaziz Z, Winter E, Daflon-Yunes N, Honorat M, Guragossian N, Marminon C, Valdameri G, Bollacke A, Guillon J, Pinaud N, Marchivie M, Cadena SM, Jose J, Le Borgne M, Di Pietro A.

Drug Des Devel Ther. 2015 Jul 3;9:3481-95. doi: 10.2147/DDDT.S84982. eCollection 2015.

6.

Synthesis, Biological Evaluation and Molecular Modeling of Substituted Indeno[1,2-b]indoles as Inhibitors of Human Protein Kinase CK2.

Alchab F, Ettouati L, Bouaziz Z, Bollacke A, Delcros JG, Gertzen CG, Gohlke H, Pinaud N, Marchivie M, Guillon J, Fenet B, Jose J, Borgne ML.

Pharmaceuticals (Basel). 2015 Jun 8;8(2):279-302. doi: 10.3390/ph8020279.

7.

Functional display of heterotetrameric human protein kinase CK2 on Escherichia coli: a novel tool for drug discovery.

Gratz A, Bollacke A, Stephan S, Nienberg C, Le Borgne M, Götz C, Jose J.

Microb Cell Fact. 2015 Jun 3;14:74. doi: 10.1186/s12934-015-0263-z.

8.

Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.

Jabor Gozzi G, Bouaziz Z, Winter E, Daflon-Yunes N, Aichele D, Nacereddine A, Marminon C, Valdameri G, Zeinyeh W, Bollacke A, Guillon J, Lacoudre A, Pinaud N, Cadena SM, Jose J, Le Borgne M, Di Pietro A.

J Med Chem. 2015 Jan 8;58(1):265-77. doi: 10.1021/jm500943z. Epub 2014 Oct 16.

PMID:
25272055
9.

Biologically active carbazole derivatives: focus on oxazinocarbazoles and related compounds.

Bouaziz Z, Issa S, Gentili J, Gratz A, Bollacke A, Kassack M, Jose J, Herfindal L, Gausdal G, Døskeland SO, Mullié C, Sonnet P, Desgrouas C, Taudon N, Valdameri G, Di Pietro A, Baitiche M, Le Borgne M.

J Enzyme Inhib Med Chem. 2015 Apr;30(2):180-8. doi: 10.3109/14756366.2014.899594. Epub 2014 Apr 3.

PMID:
24697298
10.

Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.

Guillon J, Le Borgne M, Rimbault C, Moreau S, Savrimoutou S, Pinaud N, Baratin S, Marchivie M, Roche S, Bollacke A, Pecci A, Alvarez L, Desplat V, Jose J.

Eur J Med Chem. 2013 Jul;65:205-22. doi: 10.1016/j.ejmech.2013.04.051. Epub 2013 May 3.

PMID:
23711832
11.

Preparation and characterization of CK2 inhibitor-loaded cyclodextrin nanoparticles for drug delivery.

Perret F, Marminon C, Zeinyeh W, Nebois P, Bollacke A, Jose J, Parrot-Lopez H, Le Borgne M.

Int J Pharm. 2013 Jan 30;441(1-2):491-8. doi: 10.1016/j.ijpharm.2012.11.004. Epub 2012 Nov 13.

PMID:
23154152

Supplemental Content

Loading ...
Support Center